MXPA05013281A - Composiciones farmaceuticas de atorvastatina. - Google Patents

Composiciones farmaceuticas de atorvastatina.

Info

Publication number
MXPA05013281A
MXPA05013281A MXPA05013281A MXPA05013281A MXPA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A MX PA05013281 A MXPA05013281 A MX PA05013281A
Authority
MX
Mexico
Prior art keywords
atorvastatin
compositions
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
MXPA05013281A
Other languages
English (en)
Inventor
Kenneth Craig Waterman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA05013281A publication Critical patent/MXPA05013281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Una composicion farmaceutica granulada en humedo que comprende atorvastatina o una de sus sales farmaceuticamente aceptables con menos de aproximadamente 5% en peso de un aditivo constituido por una sal de metal alcalino-terreo con un desintegrante, que proporciona la atorvastatina con no mas de aproximadamente 3% de lactona de atorvastatina, basada en la relacion del area del pico de lactona comparada con las areas integradas de todos los picos relacionados con el farmaco, asi como dicha composicion farmaceutica granulada en humedo que comprende atorvastatina o una de sus sales farmaceuticamente aceptables en combinacion con al menos otro farmaco activo, metodos para preparar dichas composiciones, kits para contener dichas composiciones, y un metodo de tratar hipercolesterolemia y/o hiperlipidemia, osteoporosis, hiperplasia prostatica benigna (BPH), y la enfermedad de Alzheimer que comprende una cantidad terapeuticamente eficaz de las composiciones farmaceuticas.
MXPA05013281A 2003-06-12 2004-06-01 Composiciones farmaceuticas de atorvastatina. MXPA05013281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12
PCT/IB2004/001862 WO2004110431A1 (en) 2003-06-12 2004-06-01 Stable compositions of atorvastatin prepared with wet granulation

Publications (1)

Publication Number Publication Date
MXPA05013281A true MXPA05013281A (es) 2006-03-09

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013281A MXPA05013281A (es) 2003-06-12 2004-06-01 Composiciones farmaceuticas de atorvastatina.

Country Status (15)

Country Link
EP (1) EP1635814A1 (es)
JP (1) JP2006527260A (es)
KR (1) KR100814218B1 (es)
CN (1) CN100434069C (es)
AR (1) AR044774A1 (es)
AU (1) AU2004246868B2 (es)
BR (1) BRPI0411344A (es)
CA (1) CA2465565A1 (es)
CO (1) CO5650230A2 (es)
MX (1) MXPA05013281A (es)
NO (1) NO20060022L (es)
NZ (1) NZ543337A (es)
RU (1) RU2332211C2 (es)
TW (1) TW200503690A (es)
WO (1) WO2004110431A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2009000286A1 (en) * 2007-06-25 2008-12-31 Parmatheen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
US8414958B2 (en) * 2008-02-27 2013-04-09 Thommen Medical Ag Implant and method for the manufacture thereof
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
PE20170523A1 (es) * 2014-07-25 2017-05-17 Novartis Ag Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
US20180042851A1 (en) * 2015-03-12 2018-02-15 Fmc Corporation Solid dispersions
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
AU5328701A (en) * 2000-04-10 2001-10-23 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Also Published As

Publication number Publication date
JP2006527260A (ja) 2006-11-30
CO5650230A2 (es) 2006-06-30
RU2332211C2 (ru) 2008-08-27
EP1635814A1 (en) 2006-03-22
BRPI0411344A (pt) 2006-07-11
TW200503690A (en) 2005-02-01
AU2004246868B2 (en) 2008-01-17
NZ543337A (en) 2008-03-28
CA2465565A1 (en) 2004-12-12
AR044774A1 (es) 2005-10-05
CN100434069C (zh) 2008-11-19
CN1805741A (zh) 2006-07-19
NO20060022L (no) 2006-01-03
KR100814218B1 (ko) 2008-03-17
KR20060020666A (ko) 2006-03-06
WO2004110431A1 (en) 2004-12-23
RU2005136745A (ru) 2006-07-27
AU2004246868A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
NO20060022L (no) Stabile sammensetninger av atorvastatin fremstilt ved vat granulering
TW200509905A (en) Pharmaceutical compositions of atorvastatin
EP2305251A3 (en) Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
WO2006118948A3 (en) Therapeutic compositions
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
PT1317419E (pt) Compostos e composições de ácido cianofenoxicarboxílico para administrar agentes activos
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
NZ502449A (en) Tricyclic vasopressin agonists and their pharmaceutical use
WO2003045319A3 (en) Targeted therapeutics and uses thereof
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения
GB2426707A (en) A stable parental formulation of levomepromazine and a method for stabilizing said formulation
DE69911017D1 (en) Arylsulfonanilid-phosphate
GB2407504A (en) Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections
PL1806136T3 (pl) Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
MXPA04007560A (es) Formulaciones orales de trimetobenzamida y metodos para usar las mismas.
MXPA02012957A (es) Formulacion nueva.
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal